Holdings of PROFUND VP BIOTECHNOLOGY
ProFunds · Original filing · Compare with another fund · Report an error
- Net assets
- 41.7M $ including 40.6M $ in equities, 97.3 %
- Positions
- 147 in 6 countries
- Top ten
- 13.3 % of net assets
- Filed on
- Mar 31, 2026
Portfolio shape
Positions
| Rank | Company | Shares | Value | Weight |
|---|---|---|---|---|
| 101 | Geron Corp | 90,807 | 135.3K $ | 0.32 % |
| 102 | Day One Biopharmaceuticals Inc | 6,085 | 130.5K $ | 0.31 % |
| 103 | Precigen Inc | 32,805 | 127K $ | 0.30 % |
| 104 | Vir Biotechnology Inc | 13,814 | 123.8K $ | 0.30 % |
| 105 | KalVista Pharmaceuticals Inc | 5,888 | 118.5K $ | 0.28 % |
| 106 | CytomX Therapeutics Inc | 24,647 | 115.8K $ | 0.28 % |
| 107 | Annexon Inc | 20,890 | 115.7K $ | 0.28 % |
| 108 | Kura Oncology Inc | 13,787 | 112.1K $ | 0.27 % |
| 109 | Inhibrx Biosciences Inc | 1,620 | 108.9K $ | 0.26 % |
| 110 | SELLAS Life Sciences Group Inc | 25,634 | 108.4K $ | 0.26 % |
| 111 | Janux Therapeutics Inc | 7,783 | 108.2K $ | 0.26 % |
| 112 | Compass Therapeutics Inc | 20,129 | 106.5K $ | 0.26 % |
| 113 | Savara Inc | 19,419 | 106K $ | 0.25 % |
| 114 | Rigel Pharmaceuticals Inc | 3,872 | 104.7K $ | 0.25 % |
| 115 | Sana Biotechnology Inc | 36,338 | 104.7K $ | 0.25 % |
| 116 | Cullinan Therapeutics Inc | 7,141 | 101.5K $ | 0.24 % |
| 117 | ARS Pharmaceuticals Inc | 12,089 | 97.1K $ | 0.23 % |
| 118 | ZENAS BIOPHARMA INC | 4,950 | 96.8K $ | 0.23 % |
| 119 | Xencor Inc | 7,767 | 93.7K $ | 0.22 % |
| 120 | Replimune Group Inc | 12,176 | 93.1K $ | 0.22 % |
| 121 | Vor BioPharma Inc | 5,191 | 92.6K $ | 0.22 % |
| 122 | Sionna Therapeutics Inc | 2,275 | 91.2K $ | 0.22 % |
| 123 | ArriVent Biopharma Inc | 3,828 | 88.3K $ | 0.21 % |
| 124 | Ironwood Pharmaceuticals Inc | 22,262 | 78.1K $ | 0.19 % |
| 125 | Bicara Therapeutics Inc | 3,906 | 77.7K $ | 0.19 % |
| 126 | Prime Medicine Inc | 22,155 | 77.1K $ | 0.18 % |
| 127 | Absci Corp | 24,763 | 74.3K $ | 0.18 % |
| 128 | Altimmune Inc | 23,768 | 73.2K $ | 0.18 % |
| 129 | Emergent BioSolutions Inc | 8,756 | 72.7K $ | 0.17 % |
| 130 | Allogene Therapeutics Inc | 29,017 | 70.8K $ | 0.17 % |
| 131 | HYPERLIQUID STRATEGIES INC | 13,646 | 69.5K $ | 0.17 % |
| 132 | 4D Molecular Therapeutics Inc | 7,337 | 68.3K $ | 0.16 % |
| 133 | Vanda Pharmaceuticals Inc | 9,486 | 65.5K $ | 0.16 % |
| 134 | REGENXBIO Inc | 7,592 | 63.6K $ | 0.15 % |
| 135 | Lexeo Therapeutics Inc | 10,369 | 59.5K $ | 0.14 % |
| 136 | Verastem Inc | 11,214 | 59.4K $ | 0.14 % |
| 137 | Arbutus Biopharma Corp | 12,626 | 56.8K $ | 0.14 % |
| 138 | Myriad Genetics Inc | 12,025 | 54.1K $ | 0.13 % |
| 139 | Prothena Corp PLC | 5,474 | 53.2K $ | 0.13 % |
| 140 | Ocugen Inc | 29,074 | 52.6K $ | 0.13 % |
| 141 | Rocket Pharmaceuticals Inc | 14,512 | 52K $ | 0.12 % |
| 142 | MiMedx Group Inc | 12,707 | 50.2K $ | 0.12 % |
| 143 | Akebia Therapeutics Inc | 33,617 | 46.7K $ | 0.11 % |
| 144 | Anavex Life Sciences Corp | 14,773 | 45.4K $ | 0.11 % |
| 145 | Invivyd Inc | 31,477 | 40.9K $ | 0.10 % |
| 146 | Perspective Therapeutics Inc | 9,538 | 39.8K $ | 0.10 % |
| 147 | DAMORA THERAPEUTICS INC | 522 | 13.5K $ | 0.03 % |
Sector breakdown
- Health care 14.8 %
- Unattributed 85.2 %
Titelia classification, company by company. The unattributed share stays visible.
Currency breakdown
- USD 100.0 %
The quoted currency of each line, as declared.
Country breakdown
- United States 95.4 %
- Ireland 1.6 %
- Switzerland 1.1 %
- Bermuda 1.1 %
- British Virgin Islands 0.4 %
- Netherlands 0.4 %
Shares computed on the equity sleeve.
| Rank | Country | Lines | Value | Share |
|---|---|---|---|---|
| 1 | United States | 141 | 38.8M $ | 95.45 % |
| 2 | Ireland | 2 | 643.4K $ | 1.58 % |
| 3 | Switzerland | 1 | 441.6K $ | 1.09 % |
| 4 | Bermuda | 1 | 434.1K $ | 1.07 % |
| 5 | British Virgin Islands | 1 | 177.8K $ | 0.44 % |
| 6 | Netherlands | 1 | 151.7K $ | 0.37 % |
Cite this page
Titelia. "Holdings of PROFUND VP BIOTECHNOLOGY". https://titelia.com/en/funds/S000003965